Barinthus Biotherapeutics: which funds own it

Who owns Barinthus Biotherapeutics?

Barinthus Biotherapeutics trades in the U.S. through ADRs, certificates that represent shares of a non-U.S. company. Form 13F counts ADRs while the company reports ordinary shares, so we do not compute percentages. Holders reporting more than 5% of the ordinary shares to the SEC (Schedules 13D/13G): Frank W. Cawood, 8.4% (13G/A filed Feb 11, 2025) and International Generosity Foundation Trust, 6.7% (13D filed Apr 13, 2026). As of Jun 30, 2026, the largest ADR holders reported on Form 13F were M&g (5.2 million ADRs), HSG Holding (1.4 million ADRs) and GLR Partners (1.2 million ADRs).

Sources:13G/A by Frank W. Cawood (Feb 11, 2025) ↗13D by International Generosity Foundation Trust (Apr 13, 2026) ↗All of the company's proxy statements on EDGAR ↗

We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.

• M&g5.2 MType not verified · 12.72% of the company0
• HSG Holding1.4 MPrivate equity or venture capital · 3.48% of the company0
• GLR Partners1.2 MType not verified · 3.04% of the company0
• DC Funds642 KType not verified · 1.57% of the company0
• Rangeley Capital185 KType not verified · 0.45% of the company+26 K
• Johns Hopkins University122 KFoundation or endowment · 0.30% of the company0
• Morgan Stanley109 KBank or trading desk · 0.27% of the company+107 K
• Baird Financial Group106 KWealth adviser · 0.26% of the company0
• Citadel Advisors77 KQuant or multi-manager · 0.19% of the company−42 K
• HighTower Advisors37 KWealth adviser · 0.09% of the company0

The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.

Shares outstanding: buybacks and dilution

From the statements the company filed with the SEC (10-K). The change compares average diluted shares of each fiscal year, on today's basis: negative = it bought back more than it issued; positive = dilution. “No data” = the company does not report that item under a tag we can read; it does not mean zero.

Earnings quality and debt

From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.

Above 5% over time (13D/13G)

Each holder with its filings in order. History since December 2024.

Flagged material events (8-K)

• Sep 9, 2026Seriousfiling ↗

  Notice of delisting or failure to meet a listing rule (Item 3.01)

• Sep 1, 2026Seriousfiling ↗

  Notice of delisting or failure to meet a listing rule (Item 3.01)

• Aug 25, 2026Seriousfiling ↗

  Notice of delisting or failure to meet a listing rule (Item 3.01)

  «Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics»

• Jan 6, 2026Seriousfiling ↗

  Notice of delisting or failure to meet a listing rule (Item 3.01)

• Apr 22, 2026Routinefiling ↗

  Change in directors or officers (Item 5.02)

• Mar 31, 2026Routinefiling ↗

  Change in directors or officers (Item 5.02)

Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.